Gainers
- Rockwell Medical RMTI stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
- Biodesix BDSX shares moved upwards by 8.55% to $1.46. The market value of their outstanding shares is at $56.1 million.
- Regulus Therapeutics RGLS stock moved upwards by 6.72% to $0.25. The company's market cap stands at $37.0 million.
- Alaunos Therapeutics TCRT stock increased by 5.77% to $0.43. The market value of their outstanding shares is at $93.7 million.
- ARCA biopharma ABIO stock moved upwards by 5.6% to $2.45. The company's market cap stands at $35.3 million.
- Surgalign Holdings SRGA stock moved upwards by 5.53% to $0.25. Surgalign Holdings's trading volume hit 63.2K shares by close, accounting for 1.7% of its average volume over the last 100 days. The company's market cap stands at $49.6 million.
Losers
- ACADIA Pharmaceuticals ACAD stock declined by 7.1% to $20.81 during Monday's after-market session. Trading volume for this security closed at 73.6K, accounting for 4.9% of its average full-day volume over the last 100 days. The company's market cap stands at $3.3 billion.
- HTG Molecular Diagnostics HTGM shares decreased by 6.49% to $1.01. The company's market cap stands at $10.9 million.
- TherapeuticsMD TXMD shares fell 5.0% to $0.27. Trading volume for this security closed at 644.1K, accounting for 9.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $117.0 million.
- Zentalis Pharmaceuticals ZNTL shares fell 4.99% to $23.26. The market value of their outstanding shares is at $1.0 billion.
- Axonics AXNX shares fell 4.99% to $57.92. Axonics's trading volume hit 69.7K shares by close, accounting for 15.4% of its average volume over the last 100 days. The company's market cap stands at $2.7 billion.
- Homology Medicines FIXX stock fell 4.88% to $1.95. The company's market cap stands at $111.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in